{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:03:19Z","timestamp":1784890999796,"version":"3.55.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000808"],"award-info":[{"award-number":["82000808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation and Application Project of Medical and Public Health Technology of Wuxi Science and Technology","award":["N20202005"],"award-info":[{"award-number":["N20202005"]}]},{"name":"Major Special Fund for Translational Medicine","award":["2020ZHZD03"],"award-info":[{"award-number":["2020ZHZD03"]}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["JUSRP12048"],"award-info":[{"award-number":["JUSRP12048"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fund of Wuxi Healthcare Commission","award":["M202004"],"award-info":[{"award-number":["M202004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02216-y","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T08:01:40Z","timestamp":1697356900000},"page":"761-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A revisit of drugs and potential therapeutic targets against non-alcoholic fatty liver disease: learning from clinical trials"],"prefix":"10.1007","volume":"47","author":[{"given":"S.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,15]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68:268\u2013279","journal-title":"J Hepatol"},{"key":"2216_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri BA (2020) Therapeutic landscape for NAFLD in 2020. Gastroenterology 158:1984-1998.e1983","journal-title":"Gastroenterology"},{"key":"2216_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679\u2013689","journal-title":"Hepatology"},{"key":"2216_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40618-020-01446-8","volume":"44","author":"S Porro","year":"2020","unstructured":"Porro S et al (2020) Dysmetabolic adipose tissue in obesity: morphological and functional characteristics of adipose stem cells and mature adipocytes in healthy and unhealthy obese subjects. J Endocrinol Invest 44:921\u2013941","journal-title":"J Endocrinol Invest"},{"key":"2216_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000161","author":"Y Hosokawa","year":"2023","unstructured":"Hosokawa Y et al (2023) Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model. Hepatol Commun. https:\/\/doi.org\/10.1097\/HC9.0000000000000161","journal-title":"Hepatol Commun"},{"key":"2216_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335\u20131347","journal-title":"Hepatology"},{"key":"2216_CR7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063\u20132072","journal-title":"N Engl J Med"},{"key":"2216_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC et al (2020) Nonalcoholic steatohepatitis: a review. JAMA 323:1175\u20131183","journal-title":"JAMA"},{"key":"2216_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11\u201320","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR10","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158:1851\u20131864","journal-title":"Gastroenterology"},{"key":"2216_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908\u2013922","journal-title":"Nat Med"},{"key":"2216_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s42255-019-0140-x","volume":"1","author":"AM Diehl","year":"2019","unstructured":"Diehl AM, Farpour-Lambert NJ, Zhao L, Tilg H (2019) Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nat Metab 1:1027\u20131029","journal-title":"Nat Metab"},{"key":"2216_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/13543784.2020.1668926","volume":"29","author":"MP Johnston","year":"2020","unstructured":"Johnston MP, Patel J, Byrne CD (2020) Multi-drug approaches to NASH: what\u2019s in the development pipeline? Expert Opin Investig Drugs 29:143\u2013150","journal-title":"Expert Opin Investig Drugs"},{"key":"2216_CR14","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313:2263\u20132273","journal-title":"JAMA"},{"key":"2216_CR15","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47-64","journal-title":"J Hepatol"},{"key":"2216_CR16","doi-asserted-by":"publisher","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","volume":"111","author":"B Dewidar","year":"2020","unstructured":"Dewidar B, Kahl S, Pafili K, Roden M (2020) Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 111:154299","journal-title":"Metabolism"},{"key":"2216_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12072-019-10001-4","volume":"14","author":"KC Reimer","year":"2020","unstructured":"Reimer KC, Wree A, Roderburg C, Tacke F (2020) New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 14:8\u201323","journal-title":"Hepatol Int"},{"key":"2216_CR18","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809302","author":"AA Kolodziejczyk","year":"2019","unstructured":"Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E (2019) The role of the microbiome in NAFLD and NASH. EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.201809302","journal-title":"EMBO Mol Med"},{"key":"2216_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.chom.2020.07.007","volume":"28","author":"S Lang","year":"2020","unstructured":"Lang S, Schnabl B (2020) Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 28:233\u2013244","journal-title":"Cell Host Microbe"},{"key":"2216_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.trsl.2015.08.002","volume":"167","author":"A Federico","year":"2016","unstructured":"Federico A, Dallio M, Godos J, Loguercio C, Salomone F (2016) Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res 167:116\u2013124","journal-title":"Transl Res"},{"key":"2216_CR21","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.3748\/wjg.v23.i36.6549","volume":"23","author":"S Singh","year":"2017","unstructured":"Singh S, Osna NA, Kharbanda KK (2017) Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol 23:6549\u20136570","journal-title":"World J Gastroenterol"},{"key":"2216_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/14656566.2020.1744564","volume":"21","author":"Y Sumida","year":"2020","unstructured":"Sumida Y et al (2020) Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 21:953\u2013967","journal-title":"Expert Opin Pharmacother"},{"key":"2216_CR23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.7150\/thno.61747","volume":"12","author":"G Chen","year":"2022","unstructured":"Chen G, Kang W, Li W, Chen S, Gao Y (2022) Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies. Theranostics 12:1419\u20131439","journal-title":"Theranostics"},{"key":"2216_CR24","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison SA et al (2021) Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med 27:1262\u20131271","journal-title":"Nat Med"},{"key":"2216_CR25","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2337\/dc19-1892","volume":"43","author":"ML Hartman","year":"2020","unstructured":"Hartman ML et al (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352\u20131355","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2216_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/liv.14844","volume":"41","author":"SAM Albhaisi","year":"2021","unstructured":"Albhaisi SAM, Sanyal AJ (2021) New drugs for NASH. Liver Int 41(Suppl 1):112\u2013118","journal-title":"Liver Int"},{"key":"2216_CR27","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184\u20132196","journal-title":"Lancet"},{"key":"2216_CR28","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(19)32963-0","volume":"394","author":"M Eslam","year":"2019","unstructured":"Eslam M, Alvani R, Shiha G (2019) Obeticholic acid: towards first approval for NASH. Lancet 394:2131\u20132133","journal-title":"Lancet"},{"key":"2216_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","volume":"165","author":"V Ratziu","year":"2020","unstructured":"Ratziu V, Friedman SL (2020) Why do so many NASH trials fail? Gastroenterology 165:5\u201310","journal-title":"Gastroenterology"},{"key":"2216_CR30","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1053\/j.gastro.2021.12.250","volume":"162","author":"T Qian","year":"2022","unstructured":"Qian T et al (2022) Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology 162:1210\u20131225","journal-title":"Gastroenterology"},{"key":"2216_CR31","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2468-1253(22)00049-8","volume":"7","author":"EA Tsochatzis","year":"2022","unstructured":"Tsochatzis EA (2022) Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design. Lancet Gastroenterol Hepatol 7:586\u2013587","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2216_CR32","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","volume":"76","author":"Z Safari","year":"2019","unstructured":"Safari Z, G\u00e9rard P (2019) The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 76:1541\u20131558","journal-title":"Cell Mol Life Sci"},{"key":"2216_CR33","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM et al (2015) Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1:15080","journal-title":"Nat Rev Dis Primers"},{"key":"2216_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-017-0806-8","volume":"15","author":"BA Neuschwander-Tetri","year":"2017","unstructured":"Neuschwander-Tetri BA (2017) Non-alcoholic fatty liver disease. BMC Med 15:45","journal-title":"BMC Med"},{"key":"2216_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1053\/j.gastro.2021.05.008","volume":"161","author":"A Fuchs","year":"2021","unstructured":"Fuchs A et al (2021) Associations among adipose tissue immunology, inflammation, exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease. Gastroenterology 161:968-981.e912","journal-title":"Gastroenterology"},{"key":"2216_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J et al (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17:279\u2013297","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/gutjnl-2019-319664","volume":"70","author":"X Zhang","year":"2021","unstructured":"Zhang X et al (2021) Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70:761\u2013774","journal-title":"Gut"},{"key":"2216_CR38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K et al (2019) The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 16:145\u2013159","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR39","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","volume":"7","author":"X Xu","year":"2022","unstructured":"Xu X et al (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH). Signal Transduct Target Ther 7:287","journal-title":"Signal Transduct Target Ther"},{"key":"2216_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","volume":"16","author":"E Piccinin","year":"2019","unstructured":"Piccinin E, Villani G, Moschetta A (2019) Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol 16:160\u2013174","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP et al (2012) The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 56:952\u2013964","journal-title":"J Hepatol"},{"key":"2216_CR42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","volume":"73","author":"J Bates","year":"2020","unstructured":"Bates J et al (2020) Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol 73:896\u2013905","journal-title":"J Hepatol"},{"key":"2216_CR43","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba R et al (2018) GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155:1463-1473e1466","journal-title":"Gastroenterology"},{"key":"2216_CR44","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","volume":"16","author":"EJ Lawitz","year":"2018","unstructured":"Lawitz EJ et al (2018) Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 16:1983-1991e1983","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2216_CR45","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","volume":"161","author":"R Loomba","year":"2021","unstructured":"Loomba R et al (2021) TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial. Gastroenterology 161:1475\u20131486","journal-title":"Gastroenterology"},{"key":"2216_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hep.31000","volume":"72","author":"MM Syed-Abdul","year":"2020","unstructured":"Syed-Abdul MM et al (2020) Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities. Hepatology 72:103\u2013118","journal-title":"Hepatology"},{"key":"2216_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100237","volume":"3","author":"D Bhattacharya","year":"2021","unstructured":"Bhattacharya D et al (2021) Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis. JHEP Rep 3:100237","journal-title":"JHEP Rep"},{"key":"2216_CR48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1523-1755.2002.00129.x","volume":"61","author":"N Broeders","year":"2002","unstructured":"Broeders N, Abramowicz D (2002) Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 61:354\u2013355","journal-title":"Kidney Int"},{"key":"2216_CR49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","volume":"63","author":"S Francque","year":"2015","unstructured":"Francque S et al (2015) PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol 63:164\u2013173","journal-title":"J Hepatol"},{"key":"2216_CR50","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/hepr.13571","volume":"50","author":"Y Seko","year":"2020","unstructured":"Seko Y et al (2020) Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study. Hepatol Res 50:1328\u20131336","journal-title":"Hepatol Res"},{"key":"2216_CR51","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA (2017) Pemafibrate: first global approval. Drugs 77:1805\u20131810","journal-title":"Drugs"},{"key":"2216_CR52","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1210\/jc.2011-1061","volume":"96","author":"HE Bays","year":"2011","unstructured":"Bays HE et al (2011) MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab 96:2889\u20132897","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/13543784.2020.1668375","volume":"29","author":"MJ Westerouen Van Meeteren","year":"2020","unstructured":"Westerouen Van Meeteren MJ, Drenth JPH, Tjwa E (2020) Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 29:117\u2013123","journal-title":"Expert Opin Investig Drugs"},{"key":"2216_CR54","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1002\/hep4.2011","volume":"6","author":"A Vijayakumar","year":"2022","unstructured":"Vijayakumar A et al (2022) Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis. Hepatol Commun 6:2298\u20132309","journal-title":"Hepatol Commun"},{"key":"2216_CR55","doi-asserted-by":"publisher","first-page":"26687","DOI":"10.1074\/jbc.M704165200","volume":"282","author":"H Kurosu","year":"2007","unstructured":"Kurosu H et al (2007) Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 282:26687\u201326695","journal-title":"J Biol Chem"},{"key":"2216_CR56","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","volume":"71","author":"JF Dufour","year":"2022","unstructured":"Dufour JF et al (2022) Current therapies and new developments in NASH. Gut 71:2123\u20132134","journal-title":"Gut"},{"key":"2216_CR57","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal A et al (2019) Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392:2705\u20132717","journal-title":"Lancet"},{"key":"2216_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106335","volume":"104","author":"MF Abdelmalek","year":"2021","unstructured":"Abdelmalek MF et al (2021) The FALCON program: two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemp Clin Trials 104:106335","journal-title":"Contemp Clin Trials"},{"key":"2216_CR59","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1111\/bph.15427","volume":"178","author":"A Kannt","year":"2021","unstructured":"Kannt A et al (2021) Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol 178:2412\u20132423","journal-title":"Br J Pharmacol"},{"key":"2216_CR60","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/hep4.1657","volume":"5","author":"SA Harrison","year":"2021","unstructured":"Harrison SA et al (2021) Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH. Hepatol Commun 5:573\u2013588","journal-title":"Hepatol Commun"},{"key":"2216_CR61","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","volume":"29","author":"S Fiorucci","year":"2020","unstructured":"Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E (2020) Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 29:623\u2013632","journal-title":"Expert Opin Investig Drugs"},{"key":"2216_CR62","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA (2022) Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of Life. Clin Gastroenterol Hepatol 20:1354-1361.e1357","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2216_CR63","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/hep.20920","volume":"42","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, McCullough AJ, Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:987\u20131000","journal-title":"Hepatology"},{"key":"2216_CR64","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679\u2013690","journal-title":"Lancet"},{"key":"2216_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003995","volume":"3","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ et al (2013) Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open 3:e003995","journal-title":"BMJ Open"},{"key":"2216_CR66","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O'Neil","year":"2018","unstructured":"O\u2019Neil PM et al (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392:637\u2013649","journal-title":"Lancet"},{"key":"2216_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106174","volume":"97","author":"SA Harrison","year":"2020","unstructured":"Harrison SA et al (2020) Semaglutide for the treatment of non-alcoholic steatohepatitis: trial design and comparison of non-invasive biomarkers. Contemp Clin Trials 97:106174","journal-title":"Contemp Clin Trials"},{"key":"2216_CR68","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124","journal-title":"N Engl J Med"},{"key":"2216_CR69","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/clinem\/dgab722","volume":"107","author":"V Pirro","year":"2022","unstructured":"Pirro V et al (2022) Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab 107:363\u2013378","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR70","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","volume":"26","author":"JP Frias","year":"2017","unstructured":"Frias JP et al (2017) The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090\u20132746, in patients with type 2 diabetes. Cell Metab 26:343-352e342","journal-title":"Cell Metab"},{"key":"2216_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz P, Spiegelman BM (2008) Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 77:289\u2013312","journal-title":"Annu Rev Biochem"},{"key":"2216_CR72","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2020.08.016","volume":"32","author":"JA Hall","year":"2020","unstructured":"Hall JA et al (2020) Obesity-linked PPARgamma S273 phosphorylation promotes insulin resistance through growth differentiation factor 3. Cell Metab 32:665-675e666","journal-title":"Cell Metab"},{"key":"2216_CR73","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMc1006581","volume":"363","author":"F Violi","year":"2010","unstructured":"Violi F, Cangemi R (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 363:1185\u20131186 (author reply 1186)","journal-title":"N Engl J Med"},{"key":"2216_CR74","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/hep.23270","volume":"51","author":"V Ratziu","year":"2010","unstructured":"Ratziu V et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 51:445\u2013453","journal-title":"Hepatology"},{"key":"2216_CR75","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab157","author":"M Ala","year":"2021","unstructured":"Ala M (2021) SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. https:\/\/doi.org\/10.1210\/endocr\/bqab157","journal-title":"Endocrinology"},{"key":"2216_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","volume":"53","author":"Y Sumida","year":"2018","unstructured":"Sumida Y, Yoneda M (2018) Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol 53:362\u2013376","journal-title":"J Gastroenterol"},{"key":"2216_CR77","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the, L., European Association for the Study of, D. and European Association for the Study of, O","year":"2016","unstructured":"European Association for the Study of the, L., European Association for the Study of, D. and European Association for the Study of, O (2016) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388\u20131402","journal-title":"J Hepatol"},{"key":"2216_CR78","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner C, Galluzzi L, Kepp O, Kroemer G (2013) Decoding cell death signals in liver inflammation. J Hepatol 59:583\u2013594","journal-title":"J Hepatol"},{"key":"2216_CR79","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","volume":"13","author":"F Heymann","year":"2016","unstructured":"Heymann F, Tacke F (2016) Immunology in the liver\u2014from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13:88\u2013110","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR80","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1002\/hep.30506","volume":"70","author":"J Cai","year":"2019","unstructured":"Cai J, Zhang XJ, Li H (2019) The role of innate immune cells in nonalcoholic steatohepatitis. Hepatology 70:1026\u20131037","journal-title":"Hepatology"},{"key":"2216_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE (2018) Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol 15:349\u2013364","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR82","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","volume":"158","author":"RF Schwabe","year":"2020","unstructured":"Schwabe RF, Tabas I, Pajvani UB (2020) Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology 158:1913\u20131928","journal-title":"Gastroenterology"},{"key":"2216_CR83","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ (2021) Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 18:373\u2013392","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR84","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P et al (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389-397e310","journal-title":"Gastroenterology"},{"key":"2216_CR85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14:397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR86","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1002\/hep.29477","volume":"67","author":"SL Friedman","year":"2018","unstructured":"Friedman SL et al (2018) A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67:1754\u20131767","journal-title":"Hepatology"},{"key":"2216_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158156","volume":"11","author":"E Lefebvre","year":"2016","unstructured":"Lefebvre E et al (2016) Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS ONE 11:e0158156","journal-title":"PLoS ONE"},{"key":"2216_CR88","doi-asserted-by":"publisher","first-page":"9706","DOI":"10.3748\/wjg.v22.i44.9706","volume":"22","author":"N Pejnovic","year":"2016","unstructured":"Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML (2016) Galectin-3 and IL-33\/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol 22:9706\u20139717","journal-title":"World J Gastroenterol"},{"key":"2216_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison SA et al (2020) Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 73:26\u201339","journal-title":"J Hepatol"},{"key":"2216_CR90","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal AJ et al (2022) Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75:1235\u20131246","journal-title":"Hepatology"},{"key":"2216_CR91","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/hepr.13425","volume":"49","author":"Y Sumida","year":"2019","unstructured":"Sumida Y, Okanoue T, Nakajima A, Japan Study Group of, N (2019) Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res 49:1256\u20131262","journal-title":"Hepatol Res"},{"key":"2216_CR92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/apt.15030","volume":"49","author":"M Shiffman","year":"2019","unstructured":"Shiffman M et al (2019) Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3\/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 49:64\u201373","journal-title":"Aliment Pharmacol Ther"},{"key":"2216_CR93","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jhep.2019.11.024","volume":"72","author":"SA Harrison","year":"2020","unstructured":"Harrison SA et al (2020) A randomized, placebo-controlled trial of emricasan in patients with NASH and F1\u2013F3 fibrosis. J Hepatol 72:816\u2013827","journal-title":"J Hepatol"},{"key":"2216_CR94","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","volume":"17","author":"CT Frenette","year":"2019","unstructured":"Frenette CT et al (2019) Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo. Clin Gastroenterol Hepatol 17:774-783e774","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2216_CR95","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Dudek M, Knolle P (2021) Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 3:1596\u20131607","journal-title":"Nat Metab"},{"key":"2216_CR96","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","volume":"68","author":"F Marra","year":"2018","unstructured":"Marra F, Svegliati-Baroni G (2018) Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68:280\u2013295","journal-title":"J Hepatol"},{"key":"2216_CR97","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","volume":"18","author":"M Masoodi","year":"2021","unstructured":"Masoodi M et al (2021) Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol 18:835\u2013856","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR98","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","volume":"134","author":"KM Korenblat","year":"2008","unstructured":"Korenblat KM, Fabbrini E, Mohammed BS, Klein S (2008) Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134:1369\u20131375","journal-title":"Gastroenterology"},{"key":"2216_CR99","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","volume":"394","author":"SA Harrison","year":"2019","unstructured":"Harrison SA et al (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 394:2012\u20132024","journal-title":"Lancet"},{"key":"2216_CR100","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrendo.2018.10","volume":"14","author":"RA Sinha","year":"2018","unstructured":"Sinha RA, Singh BK, Yen PM (2018) Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 14:259\u2013269","journal-title":"Nat Rev Endocrinol"},{"key":"2216_CR101","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","volume":"27","author":"V Ratziu","year":"2021","unstructured":"Ratziu V et al (2021) Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 27:1825\u20131835","journal-title":"Nat Med"},{"key":"2216_CR102","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A (2020) The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 16:654\u2013667","journal-title":"Nat Rev Endocrinol"},{"key":"2216_CR103","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:1038\u20131048","journal-title":"Metabolism"},{"key":"2216_CR104","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.29897","volume":"68","author":"SA Polyzos","year":"2018","unstructured":"Polyzos SA, Kountouras J, Anastasiadis S, Doulberis M, Katsinelos P (2018) Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach? Hepatology 68:389","journal-title":"Hepatology"},{"key":"2216_CR105","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","volume":"46","author":"SA Polyzos","year":"2012","unstructured":"Polyzos SA, Kountouras J, Zavos C, Deretzi G (2012) Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46:272\u2013284","journal-title":"J Clin Gastroenterol"},{"key":"2216_CR106","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","volume":"69","author":"JF Dufour","year":"2020","unstructured":"Dufour JF, Caussy C, Loomba R (2020) Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 69:1877\u20131884","journal-title":"Gut"},{"key":"2216_CR107","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397:2212\u20132224","journal-title":"Lancet"},{"key":"2216_CR108","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41401-022-00860-3","volume":"43","author":"YY Yang","year":"2022","unstructured":"Yang YY et al (2022) Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 43:1180\u20131190","journal-title":"Acta Pharmacol Sin"},{"key":"2216_CR109","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s42255-019-0145-5","volume":"1","author":"C Priest","year":"2019","unstructured":"Priest C, Tontonoz P (2019) Inter-organ cross-talk in metabolic syndrome. Nat Metab 1:1177\u20131188","journal-title":"Nat Metab"},{"key":"2216_CR110","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M (2017) Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 13:11\u201326","journal-title":"Nat Rev Nephrol"},{"key":"2216_CR111","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/gut.2010.214577","volume":"59","author":"AR Moschen","year":"2010","unstructured":"Moschen AR et al (2010) Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59:1259\u20131264","journal-title":"Gut"},{"key":"2216_CR112","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","volume":"9","author":"W Mu","year":"2018","unstructured":"Mu W et al (2018) Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front Pharmacol 9:1566","journal-title":"Front Pharmacol"},{"key":"2216_CR113","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","volume":"15","author":"A Tripathi","year":"2018","unstructured":"Tripathi A et al (2018) The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol 15:397\u2013411","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2216_CR114","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1053\/j.gastro.2020.04.013","volume":"158","author":"JJ Maher","year":"2020","unstructured":"Maher JJ, Schattenberg JM (2020) nonalcoholic fatty liver disease in 2020. Gastroenterology 158:1849\u20131850","journal-title":"Gastroenterology"},{"key":"2216_CR115","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE (2019) Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol 15:261\u2013273","journal-title":"Nat Rev Endocrinol"},{"key":"2216_CR116","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.28864","volume":"65","author":"DB Haslam","year":"2017","unstructured":"Haslam DB (2017) Nonalcoholic steatohepatitis and the intestinal microbiota. Hepatology 65:401\u2013403","journal-title":"Hepatology"},{"key":"2216_CR117","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1186\/s13063-021-05702-x","volume":"22","author":"ES Batista","year":"2021","unstructured":"Batista ES et al (2021) Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the \u201cBrazilian Omega Study\u201d (BROS)\u2014a randomized controlled trial. Trials 22:927","journal-title":"Trials"},{"key":"2216_CR118","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","volume":"7","author":"SA Harrison","year":"2022","unstructured":"Harrison SA et al (2022) Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol 7:603\u2013616","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2216_CR119","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12072-020-10107-0","volume":"15","author":"R Yamauchi","year":"2021","unstructured":"Yamauchi R et al (2021) Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. Hepatol Int 15:392\u2013404","journal-title":"Hepatol Int"},{"key":"2216_CR120","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba R et al (2021) Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73:625\u2013643","journal-title":"Hepatology"},{"key":"2216_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103202","volume":"63","author":"Q Pan","year":"2021","unstructured":"Pan Q et al (2021) A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis. EBioMedicine 63:103202","journal-title":"EBioMedicine"},{"key":"2216_CR122","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.26717","volume":"59","author":"MJ Armstrong","year":"2014","unstructured":"Armstrong MJ, Adams LA, Canbay A, Syn WK (2014) Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:1174\u20131197","journal-title":"Hepatology"},{"key":"2216_CR123","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M (2020) The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 72:558\u2013577","journal-title":"J Hepatol"},{"key":"2216_CR124","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera O, Tailleux A, Lefebvre P, Staels B (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152:1679-1694.e1673","journal-title":"Gastroenterology"},{"key":"2216_CR125","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","volume":"76","author":"F Bessone","year":"2018","unstructured":"Bessone F, Razori MV, Roma MG (2018) Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci 76:99\u2013128","journal-title":"Cell Mol Life Sci"},{"key":"2216_CR126","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison SA et al (2018) Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology 155:1140\u20131153\u00a0","journal-title":"Gastroenterology"},{"key":"2216_CR127","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","volume":"5","author":"G Raghu","year":"2017","unstructured":"Raghu G et al (2017) Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med 5:22\u201332","journal-title":"Lancet Respir Med"},{"key":"2216_CR128","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","volume":"160","author":"SA Harrison","year":"2021","unstructured":"Harrison SA et al (2021) Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology 160:219\u2013231.e211","journal-title":"Gastroenterology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02216-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02216-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02216-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T02:17:56Z","timestamp":1711505876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02216-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":128,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02216-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"assertion":[{"value":"2 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors declared any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not include research on human participants and\/or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}